Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma - Authors' reply.
Lancet Oncol
; 22(8): e343-e344, 2021 08.
Article
in En
| MEDLINE
| ID: mdl-34339647
Full text:
1
Database:
MEDLINE
Main subject:
Melanoma
Limits:
Humans
Language:
En
Journal:
Lancet Oncol
Journal subject:
NEOPLASIAS
Year:
2021
Type:
Article
Affiliation country:
Australia